- Posted Monday April 26, 2004
TGen Names Feigal VP of Clinical Sciences, Deputy Scientific Director
April 26, 2004
Ellen G. Feigal, MD, a leading cancer researcher, has joined the Translational Genomics Research Institute (TGen) as its Vice President of Clinical Sciences and Deputy Scientific Director.
"Dr. Feigal's administrative and scientific experience fit well with TGen's long-term vision," said TGen President Dr. Jeffrey Trent. "Her knowledge in the area of cancer research, and her ability to move effortlessly between the laboratory and administrative settings make her a major contributor toward fulfilling TGen's overall mission and the vision of building the lifesciences sector in Arizona."
As Vice President of Clinical Sciences, Dr. Feigal will work closely with TGen leadership and TGen's research and medical partners to develop and implement programs in a number of research, and health care related areas. In addition to her TGen activities, Dr. Feigal will work closely with Banner Health, one of TGen's clinical partners, to develop research activities and programs within Banner and identify clinical opportunities in areas where Banner excels and links such activities to TGen's mission and vision.
Ellen G. Feigal
TGen Vice President of Clinical Sciences & Deputy Scientific Director
"Dr. Feigal's knowledge of both medicine and science will be a key asset to Banner's clinical research planning process as Banner keeps pace with the health care changes resulting from the merger of science and medicine," said Peter Fine, CEO of Banner Health.
A noted scientist, Dr. Feigal's research activities at TGen will focus on integrating imaging and molecular diagnostics in the development of therapeutic interventions.
In her role as Deputy Scientific Director, she will work to ensure that clinical relevance is a focus of research program design, and maintain close ties with all research staff to advance their professional and TGen-related goals.
"I am excited about the opportunities and challenges associated with the creative and dynamic scientific environment at TGen, and its mission to bring 21st century scientific advances to the prevention, detection, diagnosis, and treatment of a wide range of diseases," said Dr. Feigal.
Feigal comes to TGen having served as the Acting Director of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD) for three years, and as Deputy Director of the DCTD from 1997 until her appointment as Acting Director in 2001. She oversaw programs spanning drug discovery and development, diagnostics, imaging, radiation research, biometrics, and a national network of clinical trials. From 1992 to 1997, she was a NCI Senior Investigator in the Cancer Therapy Evaluation Program, working in the areas of lung, head and neck cancer, and AIDS malignancies. She has worked extensively with industry and Federal agencies.
Dr. Feigal earned a BS in biology and a MS in molecular biology and biochemistry from the University of California Irvine, and her medical degree from the University of California Davis. She completed her residency at Stanford, and her fellowship in hematology/oncology at the University of California San Francisco. She was on the faculty at UC San Francisco and UC San Diego before joining NCI. She is certified by the American Board of Internal Medicine, and the American Board of Oncology. She sits on a number of peer review committees and editorial boards, and is the Associate Editor of the Journal of the National Cancer Institute.
Dr. Feigal is the author of numerous scientific papers and book chapters. She has also presented over 100 scientific lectures in the past seven years. In addition, she has presented selected topics on research directions and programmatic initiatives at the Board of Scientific Advisors and the National Cancer Advisory Board.
TGen's mission is to make and translate genomic discoveries into advances in human health. "Translational genomics research" is a relatively new field employing innovative advances arising from the Human Genome Project to apply to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases.